Table 4

Summary of response to study treatment

Patient IDDose levelDisease at study entryPrior therapyResponse to prior systemic treatmentCycles of lutathera, nBest response to study treatment
11ES-SCLCCarboplatin/etoposide/RTPD2PD
21ES-SCLCCarboplatin/etoposideSD2PR
31ES-SCLCCarboplatin/etoposidePD1PD
42Atypical carcinoid
  1. Cisplatin/etoposide

  2. Carboplatin/paclitaxel/bevacizumab

  1. Nintedanib

  2. Everolimus/lanreotide

NA3SD
52ES-SCLC
  1. Cisplatin/etoposide/RT

  2. Carboplatin/irinotecan

SD4NE*
62ES-SCLC
  1. Carboplatin/irinotecan

  2. Cisplatin/etoposide

PD1PD
72Atypical carcinoid Carboplatin/etoposide/lanreotidePD3SD
82High-grade neuroendocrine carcinoma
  1. Carboplatin/etoposide

  2. Everolimus/octreotide

PD1PD
92ES-SCLCCarboplatin and etoposide followed by thoracic RTPR2NE*
  • *Not evaluable due to no measurable disease.

  • ES-SCLC, extensive-stage small-cell lung cancer; NA, not available; NE, not evaluable; PD, progressive disease; PR, partial response; RT, radiotherapy; SD, stable disease.